Revance Therapeutics Stock Price, News & Analysis (NASDAQ:RVNC)

$30.25 -0.95 (-3.04 %)
(As of 02/20/2018 04:00 PM ET)
Previous Close$30.25
Today's Range$30.15 - $31.30
52-Week Range$18.00 - $37.45
Volume244,711 shs
Average Volume307,147 shs
Market Capitalization$1.10 billion
P/E Ratio-7.94
Dividend YieldN/A
Beta1.36

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics logoRevance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:RVNC
CUSIPN/A
Phone+1-510-7423400

Debt

Debt-to-Equity RatioN/A
Current Ratio7.28%
Quick Ratio7.28%

Price-To-Earnings

Trailing P/E Ratio-7.93963254593176
Forward P/E Ratio-8.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$300,000.00
Price / Sales3,606.81
Cash FlowN/A
Price / CashN/A
Book Value$6.21 per share
Price / Book4.87

Profitability

Trailing EPS($3.81)
Net Income$-89,270,000.00
Net Margins-37,161.00%
Return on Equity-67.85%
Return on Assets-57.91%

Miscellaneous

Employees106
Outstanding Shares35,770,000

Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) issued its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.95) by $0.06. The biopharmaceutical company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.05 million. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. View Revance Therapeutics' Earnings History.

Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2018?

9 Wall Street analysts have issued 12-month target prices for Revance Therapeutics' stock. Their forecasts range from $34.00 to $55.00. On average, they expect Revance Therapeutics' stock price to reach $46.11 in the next twelve months. View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:

  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (2/14/2018)
  • 2. Cantor Fitzgerald analysts commented, "RT002 injectable has the potential to be a longer lasting, safe alternative to the current products on the market, including the market leader, Botox. If RVNC can successfully develop RT002, we continue to expect the company could be in a position to submit a BLA in 2019, with a potential approval and launch in 2019/2020." (10/24/2017)

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a drop in short interest during the month of January. As of January 12th, there was short interest totalling 1,914,245 shares, a drop of 36.0% from the December 29th total of 2,988,898 shares. Based on an average daily volume of 461,170 shares, the short-interest ratio is currently 4.2 days. Approximately 6.7% of the company's stock are short sold.

Who are some of Revance Therapeutics' key competitors?

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:

  • Angus Charles Russell, Independent Chairman of the Board (Age 61)
  • L. Daniel Browne, Co-Founder, President, Chief Executive Officer, Director (Age 55)
  • Lauren P. Silvernail, Chief Financial Officer, Chief Business Officer (Age 58)
  • Abhay Joshi Ph.D., Chief Operating Officer (Age 54)
  • Todd E. Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics (Age 45)
  • Mark J. Foley, Director (Age 51)
  • Robert F. Byrnes, Independent Director (Age 72)
  • Julian S. Gangolli, Independent Director (Age 59)
  • Phyllis I. Gardner M.D., Independent Director (Age 65)
  • Philip J. Vickers, Independent Director (Age 56)

Who owns Revance Therapeutics stock?

Revance Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Essex Woodlands Management Inc. (10.74%), Franklin Resources Inc. (9.49%), BlackRock Inc. (6.06%), Bank of New York Mellon Corp (6.00%), ArrowMark Colorado Holdings LLC (4.86%) and Alliancebernstein L.P. (2.54%). Company insiders that own Revance Therapeutics stock include Curtis Ruegg, L Daniel Browne, Lauren P Silvernail and Mark J Foley. View Institutional Ownership Trends for Revance Therapeutics.

Who sold Revance Therapeutics stock? Who is selling Revance Therapeutics stock?

Revance Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Essex Woodlands Management Inc., ArrowMark Colorado Holdings LLC, Goldman Sachs Group Inc., Suffolk Capital Management LLC, Metropolitan Life Insurance Co. NY, Wells Fargo & Company MN, Rhumbline Advisers and QS Investors LLC. Company insiders that have sold Revance Therapeutics company stock in the last year include L Daniel Browne and Lauren P Silvernail. View Insider Buying and Selling for Revance Therapeutics.

Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?

Revance Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Jennison Associates LLC, Perceptive Advisors LLC, Senzar Asset Management LLC, Bank of New York Mellon Corp, Nicholas Investment Partners LP, Franklin Resources Inc. and Two Sigma Investments LP. View Insider Buying and Selling for Revance Therapeutics.

How do I buy Revance Therapeutics stock?

Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of Revance Therapeutics stock can currently be purchased for approximately $30.25.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $1.10 billion and generates $300,000.00 in revenue each year. The biopharmaceutical company earns $-89,270,000.00 in net income (profit) each year or ($3.81) on an earnings per share basis. Revance Therapeutics employs 106 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 Gateway Blvd, NEWARK, CA 94560-1152, United States. The biopharmaceutical company can be reached via phone at +1-510-7423400 or via email at [email protected]


MarketBeat Community Rating for Revance Therapeutics (RVNC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Revance Therapeutics (NASDAQ:RVNC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.893.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $46.11$46.11$37.00$37.00
Price Target Upside: 37.24% upside37.24% upside45.10% upside63.00% upside

Revance Therapeutics (NASDAQ:RVNC) Consensus Price Target History

Price Target History for Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics (NASDAQ:RVNC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018CowenSet Price TargetBuy$55.00LowView Rating Details
1/9/2018GuggenheimDowngradeBuy -> HoldN/AView Rating Details
1/5/2018MizuhoReiterated RatingBuy$54.00LowView Rating Details
1/4/2018Cantor FitzgeraldSet Price TargetBuy$50.00LowView Rating Details
12/19/2017BarclaysSet Price TargetOverweight -> Buy$40.00HighView Rating Details
12/8/2017SunTrust BanksBoost Price TargetBuy$53.00MediumView Rating Details
12/5/2017Piper Jaffray CompaniesBoost Price TargetPositive -> Overweight$28.00 -> $51.00HighView Rating Details
8/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$34.00MediumView Rating Details
6/8/2017AegisReiterated RatingBuy$36.00MediumView Rating Details
8/5/2016Brean CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Revance Therapeutics (NASDAQ:RVNC) Earnings History and Estimates Chart

Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics (NASDAQ RVNC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.95)($1.01)$0.05 million$0.08 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.93)($0.90)$0.05 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.84)($0.94)$0.07 million$0.08 millionViewListenView Earnings Details
2/27/2017Q416($0.84)($0.95)$0.07 million$0.08 millionViewListenView Earnings Details
11/3/2016Q316($0.89)($0.64)$0.08 million$0.08 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 million$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)$0.15 million$0.08 millionViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)$0.15 million$0.08 millionViewListenView Earnings Details
3/2/2015($0.53)($0.60)$0.08 million$0.08 millionViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)$0.08 millionViewN/AView Earnings Details
8/12/2014($0.68)($0.69)$0.08 millionViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)$0.16 millionViewN/AView Earnings Details
3/26/2014Q4 2013($47.11)$0.31 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Revance Therapeutics (NASDAQ:RVNC) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.74 EPS
Next Year EPS Consensus Estimate: $-3.46 EPS

Dividends

Dividend History for Revance Therapeutics (NASDAQ:RVNC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Revance Therapeutics (NASDAQ RVNC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.86%
Institutional Ownership Percentage: 91.84%
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics (NASDAQ RVNC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2017L Daniel BrowneCEOSell7,600$24.94$189,544.00133,188View SEC Filing  
11/7/2017Lauren P SilvernailCFOSell10,000$26.83$268,300.0059,006View SEC Filing  
11/7/2017Mark J FoleyDirectorBuy20,000$26.96$539,200.006,000View SEC Filing  
10/18/2017L Daniel BrowneCEOSell7,662$26.16$200,437.92140,788View SEC Filing  
10/12/2017Lauren P SilvernailCFOSell11,164$26.67$297,743.88View SEC Filing  
9/20/2017L Daniel BrowneCEOSell7,600$23.58$179,208.00148,450View SEC Filing  
8/23/2017L Daniel BrowneCEOSell22,800$22.76$518,928.00178,850View SEC Filing  
5/24/2017L Daniel BrowneCEOSell19,713$20.35$401,159.55183,932View SEC Filing  
5/22/2017L Daniel BrowneCEOSell12,287$20.20$248,197.40183,932View SEC Filing  
5/22/2017Lauren P SilvernailCFOSell1,793$20.20$36,218.6036,566View SEC Filing  
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00184,627View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00195,627View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00208,449View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00219,627View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.0024,944View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.0026,264View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.0026,264View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.0026,264View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.0017,264View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.0018,027View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.8334,001View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.0018,027View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Revance Therapeutics (NASDAQ RVNC) News Headlines

Source:
DateHeadline
BidaskClub Upgrades Revance Therapeutics (RVNC) to "Sell"BidaskClub Upgrades Revance Therapeutics (RVNC) to "Sell"
www.americanbankingnews.com - February 18 at 1:00 PM
Revance to Participate in the RBC Capital Markets 2018 Global Healthcare ConferenceRevance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 14 at 5:02 PM
Zacks Investment Research Lowers Revance Therapeutics (RVNC) to SellZacks Investment Research Lowers Revance Therapeutics (RVNC) to Sell
www.americanbankingnews.com - February 14 at 1:02 PM
Pre-Market Technical Scan on Biotech Equities -- Revance Therapeutics, Rexahn Pharma, and Riot BlockchainPre-Market Technical Scan on Biotech Equities -- Revance Therapeutics, Rexahn Pharma, and Riot Blockchain
www.bizjournals.com - February 7 at 9:33 AM
Revance Therapeutics Inc (RVNC) Given Average Rating of "Buy" by AnalystsRevance Therapeutics Inc (RVNC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 5 at 1:28 AM
Revance Therapeutics (RVNC) Upgraded to "Hold" at ValuEngineRevance Therapeutics (RVNC) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 4 at 2:52 PM
Zacks: Analysts Anticipate Revance Therapeutics Inc (RVNC) to Announce -$0.98 Earnings Per ShareZacks: Analysts Anticipate Revance Therapeutics Inc (RVNC) to Announce -$0.98 Earnings Per Share
www.americanbankingnews.com - February 2 at 5:10 PM
Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018
finance.yahoo.com - February 1 at 4:08 PM
Revance Therapeutics Inc (RVNC) Short Interest Down 36.0% in JanuaryRevance Therapeutics Inc (RVNC) Short Interest Down 36.0% in January
www.americanbankingnews.com - January 27 at 2:10 AM
Allergans Botox Business Could Stave Off Competition by Inking This Deal: RBCAllergan's Botox Business Could Stave Off Competition by Inking This Deal: RBC
finance.yahoo.com - January 25 at 9:25 AM
 Analysts Expect Revance Therapeutics Inc (RVNC) Will Post Quarterly Sales of $80,000.00 Analysts Expect Revance Therapeutics Inc (RVNC) Will Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - January 18 at 5:36 AM
Cowen Reiterates $55.00 Price Target for Revance Therapeutics (RVNC)Cowen Reiterates $55.00 Price Target for Revance Therapeutics (RVNC)
www.americanbankingnews.com - January 17 at 9:18 AM
Zacks: Analysts Expect Revance Therapeutics Inc (RVNC) to Announce -$0.98 Earnings Per ShareZacks: Analysts Expect Revance Therapeutics Inc (RVNC) to Announce -$0.98 Earnings Per Share
www.americanbankingnews.com - January 16 at 7:56 PM
SunTrust Banks Comments on Revance Therapeutics Incs FY2021 Earnings (RVNC)SunTrust Banks Comments on Revance Therapeutics Inc's FY2021 Earnings (RVNC)
www.americanbankingnews.com - January 13 at 2:40 PM
Revance Therapeutics Inc (RVNC) Receives Average Recommendation of "Buy" from BrokeragesRevance Therapeutics Inc (RVNC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 11 at 1:58 AM
Too Few Visible Catalysts For Revance Push Guggenheim to The SidelinesToo Few Visible Catalysts For Revance Push Guggenheim to The Sidelines
finance.yahoo.com - January 10 at 11:31 AM
Research Analysts Offer Predictions for Revance Therapeutics Incs FY2022 Earnings (RVNC)Research Analysts Offer Predictions for Revance Therapeutics Inc's FY2022 Earnings (RVNC)
www.americanbankingnews.com - January 8 at 8:10 PM
Revance Therapeutics (RVNC) Reports Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis - StreetInsider.comRevance Therapeutics (RVNC) Reports Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis - StreetInsider.com
www.streetinsider.com - January 8 at 3:44 PM
Analyzing Revance Therapeutics (RVNC) and Intercept Pharmaceuticals (ICPT)Analyzing Revance Therapeutics (RVNC) and Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - January 8 at 3:10 PM
Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar FasciitisRevance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis
finance.yahoo.com - January 8 at 8:35 AM
Ahead of big J.P. Morgan Healthcare Conference, companies amp ... - San Francisco Business TimesAhead of big J.P. Morgan Healthcare Conference, companies amp ... - San Francisco Business Times
www.bizjournals.com - January 7 at 11:59 PM
Revance Therapeutics (RVNC) Given Buy Rating at GuggenheimRevance Therapeutics (RVNC) Given Buy Rating at Guggenheim
www.americanbankingnews.com - January 7 at 6:40 PM
Revance Therapeutics (RVNC) Stock Rating Reaffirmed by MizuhoRevance Therapeutics (RVNC) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - January 5 at 1:06 PM
Revance Therapeutics (RVNC) Given a $50.00 Price Target by Cantor Fitzgerald AnalystsRevance Therapeutics (RVNC) Given a $50.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - January 4 at 12:40 PM
Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018
finance.yahoo.com - January 4 at 11:14 AM
Revance Therapeutics Inc (RVNC) Expected to Post Quarterly Sales of $80,000.00Revance Therapeutics Inc (RVNC) Expected to Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - January 2 at 10:06 PM
Revance Therapeutics Inc (RVNC) Expected to Post Earnings of -$0.97 Per ShareRevance Therapeutics Inc (RVNC) Expected to Post Earnings of -$0.97 Per Share
www.americanbankingnews.com - December 31 at 1:30 AM
Contrasting Revance Therapeutics (RVNC) and The CompetitionContrasting Revance Therapeutics (RVNC) and The Competition
www.americanbankingnews.com - December 22 at 3:04 AM
Revance Therapeutics (RVNC) Given a $40.00 Price Target at BarclaysRevance Therapeutics (RVNC) Given a $40.00 Price Target at Barclays
www.americanbankingnews.com - December 20 at 12:20 AM
Revance Therapeutics Inc (RVNC) to Post FY2017 Earnings of ($3.85) Per Share, Cantor Fitzgerald ForecastsRevance Therapeutics Inc (RVNC) to Post FY2017 Earnings of ($3.85) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - December 18 at 1:56 AM
Revance Therapeutics (RVNC) PT Set at $50.00 by Cantor FitzgeraldRevance Therapeutics (RVNC) PT Set at $50.00 by Cantor Fitzgerald
www.americanbankingnews.com - December 17 at 10:08 AM
Revance Therapeutics Inc (RVNC) Given Consensus Rating of "Buy" by BrokeragesRevance Therapeutics Inc (RVNC) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 17 at 2:22 AM
Revance will wait to seek backing for Botox-rival - Reuters - ReutersRevance will wait to seek backing for Botox-rival - Reuters - Reuters
www.reuters.com - December 14 at 11:34 AM
Revance Therapeutics Inc (RVNC) Expected to Announce Earnings of -$0.97 Per ShareRevance Therapeutics Inc (RVNC) Expected to Announce Earnings of -$0.97 Per Share
www.americanbankingnews.com - December 13 at 9:16 PM
Revance Announces Closing of Public Offering of Common StockRevance Announces Closing of Public Offering of Common Stock
finance.yahoo.com - December 12 at 12:04 PM
Revance Therapeutics (RVNC) Given New $53.00 Price Target at SunTrust BanksRevance Therapeutics (RVNC) Given New $53.00 Price Target at SunTrust Banks
www.americanbankingnews.com - December 8 at 4:40 PM
Revance Therapeutics Target of Unusually Large Options Trading (RVNC)Revance Therapeutics Target of Unusually Large Options Trading (RVNC)
www.americanbankingnews.com - December 8 at 1:32 AM
Pre-Market Most Active for Dec 7, 2017 : QQQ, MRNS, SAGE, HMC, VALE, STM, CIEN, MU, AKS, ABX, TVIX, RVNC - NasdaqPre-Market Most Active for Dec 7, 2017 : QQQ, MRNS, SAGE, HMC, VALE, STM, CIEN, MU, AKS, ABX, TVIX, RVNC - Nasdaq
www.nasdaq.com - December 7 at 3:44 PM
Revance Therapeutics (RVNC) Prices 5.34M Offering of Common Stock at $31/ShareRevance Therapeutics (RVNC) Prices 5.34M Offering of Common Stock at $31/Share
www.streetinsider.com - December 7 at 11:53 AM
Revance Announces Pricing of Public Offering of Common StockRevance Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 7 at 11:53 AM
Mizuho Raises Revance Therapeutics (RVNC) Price Target to $54.00Mizuho Raises Revance Therapeutics (RVNC) Price Target to $54.00
www.americanbankingnews.com - December 6 at 9:58 PM
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data - NasdaqBiotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data - Nasdaq
www.nasdaq.com - December 6 at 3:38 PM
Revance Therapeutics: Sakura Success Should Worry Allergan - Seeking AlphaRevance Therapeutics: Sakura Success Should Worry Allergan - Seeking Alpha
seekingalpha.com - December 6 at 3:38 PM
Revance Therapeutics Inc. (RVNC) Surged To A New High On Study ResultsRevance Therapeutics Inc. (RVNC) Surged To A New High On Study Results
www.rttnews.com - December 6 at 3:38 PM
Guggenheim Storms Into the Dermatology Space; Initiates Buy on Revance Therapeutics, Inc. (RVNC)Guggenheim Storms Into the Dermatology Space; Initiates Buy on Revance Therapeutics, Inc. (RVNC)
finance.yahoo.com - December 6 at 3:38 PM
Stocks Showing Market Leadership: Revance Therapeutics Earns 97 RS RatingStocks Showing Market Leadership: Revance Therapeutics Earns 97 RS Rating
finance.yahoo.com - December 6 at 3:38 PM
Mid-Afternoon Market Update: Francescas Drops On Earnings Miss; Revance Therapeutics Shares Gain - NasdaqMid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain - Nasdaq
www.nasdaq.com - December 6 at 8:47 AM
36 Biggest Movers From Yesterday - Benzinga36 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - December 6 at 8:47 AM
Today’s Research Reports on Stocks to Watch: Revance Therapeutics and Adamis PharmaceuticalsToday’s Research Reports on Stocks to Watch: Revance Therapeutics and Adamis Pharmaceuticals
finance.yahoo.com - December 6 at 8:47 AM
Guggenheim Initiates Coverage on Revance Therapeutics (RVNC)Guggenheim Initiates Coverage on Revance Therapeutics (RVNC)
www.americanbankingnews.com - December 5 at 8:48 PM

SEC Filings

Revance Therapeutics (NASDAQ:RVNC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Revance Therapeutics (NASDAQ:RVNC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Revance Therapeutics (NASDAQ RVNC) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.